Have Any Questions?


Your Current Position:Home >> Pipeline >> Immuno-Oncology


Category Description :

MabSpace has established a pipeline of therapeutic antibodies targeting various compoents of the tumor microenvironment. The lead asset is a second generation blocking PD-L1 ab with unique pH-dependent antigen binding and recycling properties. To enable combination therapy, MabSpace has developed antibodies targeting angiogeneic receptor VEGFR2, agonist antibody targeting OX40 for enhancing T cell activities and suppressing regulatory T cells, as well as antibody targeting CSF1R for the inhibition of immune suppresiion mediated by tumor associated macrophage.  In addition, MabSpace has ongoing projects targeting dendritic cells and other checkpoint inhibitors.



No relevant information

Copyright © 2017 Mabspace Biosciences All rights reserved